The pivotal trial of Nexstim’s Navigated Brain Therapy (NBT) System in treating stroke patients has failed to meet its primary endpoint. We suspend our financial forecasts and valuation while Nexstim reviews its next strategic steps. It estimates its cash reach until Q316.
01 Mar 2016
NICHE stroke rehab trial fails its primary endpoint
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
NICHE stroke rehab trial fails its primary endpoint
The pivotal trial of Nexstim’s Navigated Brain Therapy (NBT) System in treating stroke patients has failed to meet its primary endpoint. We suspend our financial forecasts and valuation while Nexstim reviews its next strategic steps. It estimates its cash reach until Q316.